NVCN - Neovasc Inc.

NasdaqCM - NasdaqCM Delayed Price. Currency in USD
0.5210
-0.0175 (-3.25%)
At close: 3:59PM EDT
Stock chart is not supported by your current browser
Previous Close0.5385
Open0.5380
Bid0.5000 x 1200
Ask0.5390 x 1000
Day's Range0.5210 - 0.5400
52 Week Range0.3700 - 5.0000
Volume993,062
Avg. Volume3,056,817
Market Cap39.24M
Beta (3Y Monthly)2.44
PE Ratio (TTM)N/A
EPS (TTM)N/A
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target EstN/A
Trade prices are not sourced from all markets
All
News
Press Releases
  • CNW Group2 days ago

    Tiara™ Featured in Presentation at 11th Annual TVT 2019

    VANCOUVER , June 17, 2019 /CNW/ - Neovasc Inc. ("Neovasc" or the "Company") (NASDAQ, TSX: NVCN), a leader in the development of minimally invasive transcatheter mitral valve replacement technologies and in the development of minimally invasive devices for the treatment of refractory angina, today announced that its Tiara™ ("Tiara") transcatheter mitral valve replacement device was featured in a presentation at the 11th Annual Transcatheter Valve Therapy Conference ("TVT 2019"). In a presentation titled "The TIARA Program: Attributes, Challenges, and Early Clinical Data" Dr. Anson Cheung , Clinical Professor of Surgery and Director of Cardiac Transplant of British Columbia , and Principal Investigator for the Tiara Early Feasibility Study at St Paul's Hospital, Vancouver Canada , provided an update on the latest progress on the Tiara, including the challenging anatomical considerations,  patient characteristics,  procedural outcomes, and symptom improvement of patients treated with Tiara.

  • PR Newswire12 days ago

    Neovasc Announces Nasdaq Continuing to Monitor Minimum Market Value Deficiency Following 10 Consecutive Business Days Above US$35 Million

    VANCOUVER, June 7, 2019 /PRNewswire/ - Neovasc Inc. ("Neovasc" or the "Company") (NASDAQ, TSX: NVCN) announced today that following 10 consecutive business days with a market value of listed securities ("MVLS") of over US$35 million, the Company has been advised by staff of The Nasdaq Stock Market LLC ("Nasdaq") that the Nasdaq will exercise its discretion to continue to monitor the Company's MVLS pursuant to Nasdaq Listing Rule 5810(c)(3)(G) in connection with the Company's deficiency under the US$35 million minimum MVLS requirement. Nasdaq Listing Rule 5810(c)(3)(G) provides that Nasdaq staff may require satisfaction of the US$35 million minimum MVLS requirement for a period in excess of 10 consecutive business days, but generally no more than 20 consecutive business days, before determining that the Company has demonstrated an ability to maintain long-term compliance.

  • PR Newswire15 days ago

    Neovasc Inc. Reports Results of Annual General and Special Meeting of Shareholders and Provides Update on Neovasc Reducer™

    VANCOUVER, June 4, 2019 /PRNewswire/ - Neovasc Inc. ("Neovasc" or the "Company") (NASDAQ, TSX: NVCN) is pleased to announce the results of the votes on matters considered at its Annual General and Special Meeting of Shareholders held on June 4, 2019 in Vancouver, B.C. (the "Meeting"). At the Meeting, the shareholders of the Company (the "Shareholders") re-elected board members Steven Rubin, Paul Geyer, Doug Janzen, Dr. Jane Hsiao and Alexei Marko and elected Fred Colen to serve in office until the next annual meeting or until their successors are duly elected or appointed. At the Meeting, the Shareholders also approved resolutions authorizing the Company's Board of Directors to, at their discretion, execute a common share consolidation (72.43% of votes cast in favour) and re-appointing Grant Thornton LLP, Chartered Accountants as auditors of the Company.

  • PR Newswire22 days ago

    Neovasc Announces Publication of Peer-Reviewed Article in European Heart Journal Concluding Positive Cost-Effectiveness of the Neovasc Reducer™

    VANCOUVER, May 28, 2019 /PRNewswire/ - Neovasc Inc. ("Neovasc" or the "Company") (NVCN)(NVCN), a leader in the development of minimally invasive transcatheter mitral valve replacement technologies and in the development of minimally invasive devices for the treatment of refractory angina, today announced that the European Heart Journal, Quality of Care and Clinical Outcomes has published a peer-reviewed article indicating the cost effectiveness of the Neovasc Reducer™ ("Reducer") as an effective therapy for patients suffering from refractory angina, and its positive impact on healthcare burden.

  • PR Newswire27 days ago

    New Tiara and Reducer Data Presented in Several Presentations at the EuroPCR 2019 Conference in Paris

    VANCOUVER, May 23, 2019 /PRNewswire/ - Neovasc Inc. ("Neovasc" or the "Company") (NVCN)(NVCN), a leader in the development of minimally invasive transcatheter mitral valve replacement technologies and in the development of minimally invasive devices for the treatment of refractory angina, today announced that new data for its Tiara™ ("Tiara") transcatheter mitral valve replacement device and Neovasc Reducer™ ("Reducer") device for the treatment of refractory angina were presented in several presentations at the EuroPCR 2019 Conference held this week in Paris, France.

  • PR Newswire28 days ago

    Neovasc Announces Positive Two-Year Follow-up Safety and Efficacy Data for the Neovasc Reducer™ in a Peer Reviewed Article in the International Journal of Cardiology

    VANCOUVER, May 22, 2019 /PRNewswire/ - Neovasc Inc. ("Neovasc" or the "Company") (NVCN)(NVCN), a leader in the development of minimally invasive transcatheter mitral valve replacement technologies and in the development of minimally invasive devices for the treatment of refractory angina, today announced that the International Journal of Cardiology has published a peer reviewed article regarding long term sustained efficacy and safety of the Reducer therapy in 50 patients suffering from refractory disabling angina. "This study shows us that the Reducer has a sustained therapeutic effect at two years across a large patient population. In addition, we believe this study provides valuable long-term safety data that further supports cardiologists use of the Reducer as a therapeutic option for patients suffering from refractory angina," commented Prof. Shmuel Banai, Medical Director of Neovasc.

  • PR Newswirelast month

    Neovasc Announces Closing of Private Placement of Convertible Debt and Common Shares for Gross Proceeds of US$11.5 Million

    VANCOUVER, May 16, 2019 /PRNewswire/ - Neovasc Inc. ("Neovasc" or the "Company") (NVCN)(NVCN) announced today that it has closed its previously announced private placement (the "Private Placement") of (i) a 15% original issue discount convertible debenture (the "Debenture") with a face value of US$11.5 million, for gross proceeds to the Company of US$9,775,000, and (ii) 3,349,514 common shares of the Company (the "Common Shares") at a price of US$0.515 per Common Share, for gross proceeds to the Company of US$1,725,000 (collectively, the "Offering"). The Company relied upon the exemption set forth in Section 602.1 of the TSX Company Manual, which provides that the Toronto Stock Exchange will not apply its standards to certain transactions involving eligible interlisted issuers on a recognized exchange, such as the Nasdaq Capital Market.

  • PR Newswirelast month

    Neovasc Announces Private Placement of Convertible Debt and Equity for Gross Proceeds of US$11.5 Million

    VANCOUVER, May 14, 2019 /PRNewswire/ - Neovasc Inc. ("Neovasc" or the "Company") (NVCN)(NVCN), a leader in the development of minimally invasive transcatheter mitral valve replacement technologies and in the development of minimally invasive devices for the treatment of refractory angina, announced today that it has entered into an agreement to sell to Strul Medical Group LLC ("SMG") (i) a 15% original issue discount convertible debenture (the "Debenture") with a face value of US$11.5 million, for gross proceeds to the Company of US$9,775,000, and (ii) 3,349,514 common shares of the Company ("Common Shares") at a price of US$0.515 per Common Share, for gross proceeds to the Company of US$1,725,000 (collectively, the "Offering").

  • PR Newswirelast month

    /C O R R E C T I O N from Source -- Neovasc Inc./

    The news release, Neovasc Announces First Quarter 2019 Financial Results, published at 4:00 p.m. ET on May 9, 2019 inadvertently included a statement that the Company had announced a financing. While the Company is always considering ways to improve its capital position on terms that the Company believes are favorable, there can be no assurance that any financing will be completed.

  • CNW Grouplast month

    Neovasc Announces Treatment of 1,000th Refractory Angina Patient with Neovasc Reducer™

    This is especially true when these people suffer from refractory angina, which is angina that persists despite optimal drug therapy and revascularization. "We are pleased to have treated the 1,000th patient to receive the Reducer therapy at the Inselspital Universitätsspital Bern ". The Reducer therapy now totals medical evidence spanning 1,000 patients and 14 years of follow up.

  • PR Newswire2 months ago

    Neovasc to Announce First Quarter 2019 Financial Results on Thursday, May 9th

    Conference Call Scheduled for 4:30 pm Eastern Time on May 9 th   NASDAQ, TSX: NVCN VANCOUVER , May 3, 2019 /PRNewswire/ - Neovasc, Inc. ("Neovasc" or the "Company") (NASDAQ: NVCN) (TSX: ...

  • PR Newswire2 months ago

    Neovasc Provides Highlights from Annual Conference of the DGK, the German Society of Cardiology; Symposium Generates Growing Support for Reducer

    VANCOUVER, April 26, 2019 /PRNewswire/ - Neovasc Inc. ("Neovasc" or the "Company") (NVCN)(NVCN), a leader in the development of minimally invasive transcatheter mitral valve replacement technologies and in the development of minimally invasive devices for the treatment of refractory angina, today provided highlights from the  85th Annual Conference of the German Society of Cardiology ("DGK"), which is taking place in Mannheim, Germany, April 24 – 27, 2019. Prof. Gori (Mainz) and Prof. Reinecke (Münster) chaired a symposium on the Reducer, which included presentations from several physicians, incl.

  • CNW Group2 months ago

    Neovasc Announces Resolution of Last Remaining Active Litigation

    VANCOUVER , April 17, 2019 /CNW/ - Neovasc Inc. ("Neovasc" or the "Company") (NVCN)(NVCN), a leader in the development of minimally invasive transcatheter mitral valve replacement technologies and in the development of minimally invasive devices for the treatment of refractory angina, today announced that the Company has resolved the three claims for correction of patent inventorship made by Edwards Lifesciences CardiAQ LLC ("CardiAQ") in the United States District Court for the District of Massachusetts ("the Court"). Its products include the Neovasc Reducer™ (the "Reducer"), for the treatment of refractory angina, which is not currently commercially available in the United States and has been commercially available in Europe since 2015, and the Tiara™, for the transcatheter treatment of mitral valve disease, which is currently under clinical investigation in the United States , Canada and Europe .